Allergic Alarms: Type I Hypersensitivity Quiz

Type I hypersensitivity is the most common form of allergic reaction and is mediated by IgE antibodies. It occurs when the immune system mounts an exaggerated response to otherwise harmless substances called allergens. Common manifestations include hay fever, allergic asthma, food allergies, and anaphylaxis. The reaction involves IgE-sensitized mast cells and basophils that release inflammatory mediators upon allergen re-exposure.

IgE is the key antibody class involved in Type I hypersensitivity. During sensitization, allergen-specific IgE is produced and binds to high-affinity Fc-epsilon-RI receptors on the surface of mast cells and basophils. Upon subsequent allergen exposure, cross-linking of bound IgE triggers degranulation and release of inflammatory mediators including histamine, leukotrienes, and prostaglandins, producing the allergic response.

Sensitization is the first stage of a Type I hypersensitivity reaction. During this phase, an allergen is processed by antigen-presenting cells and presented to Th2 cells, which drive B cells to produce allergen-specific IgE antibodies. These IgE antibodies bind to mast cells and basophils. No symptoms occur at this stage, but the immune system is now primed to react upon future allergen exposure.

Mast cells and basophils are the primary effector cells in Type I hypersensitivity. Both cell types express high-affinity IgE receptors (Fc-epsilon-RI) on their surface, allowing allergen-specific IgE to bind. When an allergen cross-links these bound IgE molecules, it triggers rapid degranulation and release of preformed and newly synthesized inflammatory mediators that drive the allergic response.

Mast cell granules contain several preformed mediators that are rapidly released upon degranulation. Histamine causes vasodilation, increased vascular permeability, and smooth muscle contraction. Heparin has anticoagulant properties and supports the inflammatory response. Tryptase is a serine protease used clinically as a marker of mast cell activation. These mediators are responsible for the immediate symptoms of allergic reactions.

Type I hypersensitivity has two distinct phases. The early or immediate phase occurs within minutes of allergen exposure due to preformed mediator release from mast cells. The late-phase response occurs 4 to 8 hours later and is driven by newly synthesized lipid mediators such as leukotrienes and prostaglandins, as well as cytokines that recruit eosinophils and other inflammatory cells to the site.

IL-4 is the master cytokine driving both Th2 cell differentiation and IgE class switching in B cells. During allergen sensitization, Th2 cells produce IL-4, which signals B cells to switch their antibody production from IgM to IgE. IL-4 also promotes the Th2 environment that sustains allergic inflammation. This makes IL-4 and its signaling pathway a key target in allergy and asthma research.

Eosinophils are recruited to sites of allergic inflammation during the late-phase response, driven by cytokines such as IL-5 and chemokines including eotaxin. Once at the site, eosinophils release cytotoxic proteins such as major basic protein and eosinophil cationic protein, which damage surrounding tissues. Eosinophil accumulation contributes significantly to the chronic tissue damage seen in persistent allergic conditions such as asthma.

During the late-phase response, activated mast cells and eosinophils synthesize lipid mediators from arachidonic acid. Leukotrienes cause prolonged bronchoconstriction and mucus secretion, contributing significantly to asthma symptoms. Prostaglandins induce vasodilation and pain sensitization. Platelet-activating factor promotes platelet aggregation and amplifies inflammation. Unlike histamine, these mediators are not preformed but are synthesized following mast cell activation.

Diagnosing Type I hypersensitivity involves identifying allergen-specific IgE. Skin prick tests introduce small amounts of allergens into the skin and a wheal and flare reaction indicates IgE-mediated sensitivity. Serum total and allergen-specific IgE levels can also be measured using immunoassays. Together, these methods help clinicians identify specific allergen triggers and guide appropriate avoidance strategies and treatment plans.

Antihistamines work by competitively blocking histamine H1 receptors on blood vessels, smooth muscle, and sensory neurons, preventing histamine from binding and exerting its effects. This reduces symptoms such as itching, sneezing, runny nose, and urticaria. Antihistamines do not prevent mast cell degranulation or IgE production and are less effective against late-phase symptoms driven by leukotrienes and prostaglandins.

IL-5 is a cytokine produced predominantly by Th2 cells and innate lymphoid cells type 2 (ILC2s). It is the primary driver of eosinophil differentiation in the bone marrow, eosinophil release into the bloodstream, and eosinophil survival at sites of allergic inflammation. Therapeutic antibodies targeting IL-5 or its receptor, such as mepolizumab, are used to treat severe eosinophilic asthma by reducing eosinophil levels.

Allergic rhinitis, atopic dermatitis, and allergic asthma are all classic manifestations of Type I IgE-mediated hypersensitivity. Allergic rhinitis involves nasal mucosal mast cell activation. Atopic dermatitis involves skin inflammation driven by IgE and Th2 cytokines. Allergic asthma features airway mast cell and eosinophil activity. Contact dermatitis from poison ivy is a Type IV cell-mediated reaction involving T cells, not IgE.

Allergen immunotherapy, also known as desensitization or allergy shots, involves administering progressively increasing doses of an allergen to reprogram the immune response. Over time, it shifts the response from Th2-driven IgE production toward regulatory T cell activity, increased IgG4 production, and reduced mast cell sensitivity. This long-term tolerance induction can significantly reduce or eliminate allergic symptoms to specific allergens.

Fc-epsilon-RI is the high-affinity receptor for the Fc region of IgE expressed on mast cells and basophils. When allergen-specific IgE antibodies bind to Fc-epsilon-RI, the cells become sensitized. Upon re-exposure to the allergen, it cross-links adjacent IgE-Fc-epsilon-RI complexes, triggering intracellular signaling cascades that result in mast cell degranulation and the release of allergic inflammatory mediators.